Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 12, 2020
- Accepted in final form October 29, 2020
- First Published December 24, 2020.
Author Disclosures
- Thanos Tsaktanis, MD (ge56naq{at}mytum.de),
- Tobias Beyer, MSc (t.beyer{at}tum.de),
- Lucy Nirschl, BS (lucy.nirschl{at}tum.de),
- Mathias Linnerbauer, MSc (mathias.linnerbauer{at}gmail.com),
- Verena Grummel (v.grummel{at}tum.de),
- Mathias Bussas, MSc (matthias.bussas{at}mri.tum.de),
- Emily Tjon, MSc (emilyctjon{at}gmail.com),
- Mark Mühlau, MD (mark.muehlau{at}tum.de),
- Thomas Korn, MD (thomas.korn{at}tum.de),
- Bernhard Hemmer, MD (hemmer{at}tum.de),
- Francisco J. Quintana, PhD (fquintana{at}rics.bwh.harvard.edu) and
- Veit Rothhammer, MD
- Thanos Tsaktanis, MD (ge56naq{at}mytum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Beyer, MSc (t.beyer{at}tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG, RO4866/2-1)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lucy Nirschl, BS (lucy.nirschl{at}tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mathias Linnerbauer, MSc (mathias.linnerbauer{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Verena Grummel (v.grummel{at}tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mathias Bussas, MSc (matthias.bussas{at}mri.tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emily Tjon, MSc (emilyctjon{at}gmail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Mühlau, MD (mark.muehlau{at}tum.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Competence Network Multiple Sclerosis (German Ministry for Research and Education, 01GI1604A), PI, 3 yearsGerman Research Foundation (DFG SPP2177, Radiomics: Next Generation of Biomedical Imaging, project number 428223038, 3 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Korn, MD (thomas.korn{at}tum.de),
NONE
NONE
(1) Novartis (2) Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Deutsche Forschungsgemeinschaft (DFG): KO2964/2-1, KO2964/3-1, KO2964/4-1, KO2964/5-1, SFB1054- B06, TR128-A07, TR274-A01, Synergy EXC2145. European Research Council (ERC): CoG647215
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bernhard Hemmer, MD (hemmer{at}tum.de),
Advisory Boards for Novartis, he has served as DMSC member for AllergyCare, TG Therapeutics and Polpharma Biologics
Me or my institution have received speaker honoraria from Desitin
Excemed
Editorial board member of Jama Neurology, Experimental Neurology and Multiple sclerosis Journal
I hold part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulati on of MS patients and one for genetic determinants of neutralizing antibodies to interferon β
NONE
NONE
NONE
NONE
NONE
NONE
(1) Regeneron - not related
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francisco J. Quintana, PhD (fquintana{at}rics.bwh.harvard.edu) and
NONE
NONE
NONE
2012 Editorial Board Member Systems Biomedicine 2012 Editorial Board Member Inmunologia (Spain) 2013- Associate Editor Immunology (UK) 2013- Senior Editorial Board Member American Journal of Clinical and Experimental Immunology 2014- Advisory Board MemberSeminars in Immunopathology
NONE
NONE
NONE
Teva, Blueprint Medicines, AnTolRx
NONE
NONE
NONE
1. EMD-Serono 2. Sanofi 3. Novartis 4. Teva 5. ONO
(1) NIH, R00 AI075285-01A2, Role PI, 2010-2012, (2) NIH, R01 AI093903-01, Role PI, 2011Â2016, (3) NIH, K99AI075285-01A2, Role PI, 2009-2010, (4) NIH, 1R01NS102807-01A1, role PI, 09/01/18 Â 08/31/23, (5) NIH, R01 ES025530-02, role PI, 06/01/16 Â 05/31/21, (6) NMSS, JF 2161-A-5, role PI, 07/01/14 Â 06/30/19, (7) American Cancer Soc., 126566-RSG-14-198-01-LIB, role PI, 01/01/15 Â 12/31/18, (8) NMSS, RR-1601-07385, role PI, 10/01/16 Â 09/30/19, (9) Israel Cancer Research Fund, 15-975-ICG, role PI, 09/01/16 Â 08/30/19, (10) NIH-NIAID, 1R01AI126880-01A1, role PI, 02/01/17 Â 01/31/22, (11) NIH-NIAID, 2R01HL095722-06A1, role PI, 09/01/15 Â 08/31/20, (12) NMSS, PA-1604-08459, role PI, 06/01/17 Â 05/31/21, (13) NMSS, PA-1604-08459, role PI, 06/01/17 Â 05/31/21, (14) King Abdulaziz City for Science & Technology, 117427, role PI, 06/01/17 Â 05/31/18, (15) NIH, 5R01DK108894-01, role Co-I, 02/01/17 Â 01/31/22,
(1) Harvard Medical School, Diversity and Community Partnership Faculty Fellowship, Role PI, 2010-2012, (2) BADERC, Pilot and Feasibility Award (Quintana), Role PI, 2010-2012
(1) NMSS, RG4111A1/1, Role PI, 2009-2012, (2) NMSS, RG4048A11, Role Research Associate, 2008-2011
AnTolRx
NONE
NONE
NONE
NONE
NONE
- Veit Rothhammer, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis Pharmaceuticals, Research Support
German Research Foundation, RO4866, PI, 2018 - 2023 European Research Council, HICI, 2020 - 2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (T.T., T.B., L.N., M.L., V.G., M.B., M.M., T.K., B.H., V.R.), Klinikum rechts der Isar, Technical University of Munich; Department of Neurology (T.T., V.R.), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuernberg; Munich Cluster for Systems Neurology (SyNergy) (T.K., B.H.), Germany; Ann Romney Center for Neurologic Diseases (E.T., F.J.Q.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard (F.J.Q.), Cambridge, MA; and TUM-Neuroimaging Center (M.B., M.M.), Klinikum rechts der Isar, Technische Universität München, Germany.
- Correspondence
Dr. Rothhammer veit.rothhammer{at}fau.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple SclerosisAna Cirac, Thanos Tsaktanis, Tobias Beyer et al.Neurology: Neuroimmunology & Neuroinflammation, July 23, 2021 -
Article
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSVeit Rothhammer, Davis M. Borucki, Maria Isabel Garcia Sanchez et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017 -
Articles
A reassessment of the plateauing relationship between T2 lesion load and disability in MSMaria Pia Sormani, Marco Rovaris, Giancarlo Comi et al.Neurology, September 30, 2009 -
Editorial
Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activityJoseph J. Sabatino, Jr, Scott S. Zamvil et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017